Bioheart finally limped across the IPO goal line yesterday, but it was a Pyhrric victory. The startup, which once sought $70 million, ended up netting as little as $1.5 million. And almost half of that amount came directly from Bioheart founder Henry Leonhardt instead of outside investors.
Bioheart, of course, has had no shortage of problems, which we've chronicled over at VentureBeat Life Sciences. For the latest installment, see here.